{
    "clinical_study": {
        "@rank": "147990", 
        "arm_group": {
            "arm_group_label": "BMN190", 
            "arm_group_type": "Experimental", 
            "description": "recombinant human tripeptidyl peptidase-1 (rhTPP1)"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether BMN 190 is safe and effective in the\n      treatment of patients with Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)\n      disease."
        }, 
        "brief_title": "Safety and Efficacy Study of BMN190 for the Treatment of Patients With CLN2 Disease", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Jansky-Bielschowsky Disease", 
            "Batten Disease", 
            "Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2", 
            "CLN2 Disease"
        ], 
        "condition_browse": {
            "mesh_term": "Neuronal Ceroid-Lipofuscinoses"
        }, 
        "detailed_description": {
            "textblock": "The purpose of this study is to determine whether BMN 190 is safe and effective in the\n      treatment of patients with Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)\n      disease. This is an open label Phase 1/2 study conducted in patients with CLN2 disease.\n      Efficacy measures (disease rating scale and MRI) will be compared to a natural history\n      control.\n\n      The study will be conducted under cGCP and patients will be closely monitored."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Has a diagnosis of CLN2 determined by TPP1 enzyme activity (dried blood spot)\n             available at study entry. If no genotype information is available, blood will be\n             collected for CLN2 gene analysis at baseline. In addition, blood for TPP1 enzyme\n             activity (dried blood spot) will be collected at baseline to be analyzed centrally\n\n          -  Has mild to moderate disease documented by a two-domain score of 3- 6 on motor and\n             language domains of the Hamburg Scale, with a score of at least 1 in each of these\n             two domains\n\n          -  Written informed consent from parent or legal guardian and assent from subject, if\n             appropriate\n\n          -  Has the ability to comply with protocol requirements, in the opinion of the\n             investigator\n\n        Exclusion Criteria:\n\n          -  Is less than 3 years old at enrollment\n\n          -  Has another inherited neurologic disease, e.g. other forms of CLN or seizures\n             unrelated to CLN2 (patients with febrile seizures may be eligible)\n\n          -  Requires ventilation support, except for noninvasive support at night\n\n          -  Has received stem cell, gene therapy, or ERT for CLN2\n\n          -  Has contraindications for neurosurgery (e.g., congenital heart disease, severe\n             respiratory impairment, or clotting abnormalities)\n\n          -  Has contraindications for MRI scans (e.g., cardiac pacemaker, metal fragment or chip\n             in the eye, aneurysm clip in the brain)  - Has generalized motor status epilepticus\n             within 4 weeks before the First Dose visit, taking care that status epilepticus is on\n             clinical examination and not only electroencephalogram (EEG) (enrollment may be\n             postponed)\n\n          -  Has severe infection (e.g., pneumonia, pyelonephritis, or meningitis) within 4 weeks\n             before the First Dose visit (enrollment may be postponed)\n\n          -  Has a medical condition or extenuating circumstance that, in the opinion of the\n             investigator, might compromise the subject's ability to comply with the protocol\n             requirements or compromise the subject's well being, safety, or clinical\n             interpretability"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "16 Years", 
            "minimum_age": "3 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01907087", 
            "org_study_id": "190-201"
        }, 
        "intervention": {
            "arm_group_label": "BMN190", 
            "description": "30-300 mg ICV infusion administered every other week for at least 48 weeks.", 
            "intervention_name": "BMN 190", 
            "intervention_type": "Biological", 
            "other_name": "recombinant human tripeptidyl peptidase-1 (rhTPP1)"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Late infantile Neuronal Ceroid Lipofuscinosis Type 2", 
            "LINCL", 
            "NCL2", 
            "CLN2", 
            "Jansky-Bielschowsky disease"
        ], 
        "lastchanged_date": "March 21, 2014", 
        "location": [
            {
                "contact": {
                    "email": "an.schulz@uke.de", 
                    "last_name": "Angela Schulz, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany", 
                        "zip": "20246"
                    }, 
                    "name": "University Hamburg-Eppendorf"
                }, 
                "investigator": {
                    "last_name": "Angela Schulz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Ruth.Williams@gstt.nhs.uk", 
                    "last_name": "Ruth Williams, MD"
                }, 
                "contact_backup": {
                    "email": "Rachael.Pennington@gstt.nhs.uk", 
                    "last_name": "Rachael Pennington, RN"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "WC2R 2LS"
                    }, 
                    "name": "Evelina Children's Hospital"
                }, 
                "investigator": {
                    "last_name": "Ruth Williams, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease", 
        "overall_contact": {
            "email": "jnuttall@bmrn.com", 
            "last_name": "Janet Nuttall, MPH"
        }, 
        "overall_contact_backup": {
            "email": "djacoby@bmrn.com", 
            "last_name": "David Jacoby, MD"
        }, 
        "overall_official": {
            "affiliation": "BioMarin Pharmaceutical", 
            "last_name": "David Jacoby", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Vital signs, adverse events, concomitant medications: Screening, Baseline, Weeks 1 to 49.\nPhysical examination: Screening, Baseline, Weeks 1 to 49.\nElectrocardiogram tests: Baseline, Weeks 1, 24 and 49\nClinical laboratory tests: Baseline, Weeks 1, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49\nImmunogenicity tests: Baseline, Weeks 1, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49", 
                "measure": "To evaluate the safety of every other week infusions of BMN 190 based on: vital signs, physical examination, electrocardiogram tests, clinical laboratory tests, adverse events, concomitant medications, immunogenicity tests", 
                "safety_issue": "Yes", 
                "time_frame": "48 weeks"
            }, 
            {
                "description": "Screening, baseline, Weeks 1, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49", 
                "measure": "To evaluate the efficacy of every other week infusions of BMN 190 by monitoring changes in clinical measures as measured by the CLN2 disease rating scale", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01907087"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Screening, Baseline, Weeks 1, 9, 17, 33, 49", 
                "measure": "To evaluate the efficacy of every other week infusions of BMN 190 by monitoring changes in clinical measures as measured by magnetic resonance imaging (MRI)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Weeks 1, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49", 
                "measure": "To determine the pharmacokinetic (PK) parameters of infused BMN 190 in subjects with CLN2", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }
        ], 
        "source": "BioMarin Pharmaceutical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "BioMarin Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}